A pair of analyses on the effects of COVID-related public health measures on children ties lockdowns and physical distancing to developmental delays among toddlers in Scotland and school reopenings to ...

As the Q3 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the health ...

Shares of Humana Inc. slid 6.03% to $258.16 Tuesday, on what proved to be an all-around rough trading session for the stock ...

House Judiciary Committee led by Rep. Jim Jordan demands information from major Obamacare brokers about potential enrollment ...

BofA raised the firm’s price target on Elevance Health (ELV) to $385 from $370 and keeps a Neutral rating on the shares, stating that its higher ...

Jefferies analyst Tycho Peterson cited the large addressable market for the company's PreTRM blood test for assessing pregnant women's risk of preterm birth.

As 2025 draws to a close, Elevance Health highlights how today’ s health plans are evolving to better support their members in a broader range of situations that affect health, including cancer ...

AM Best has affirmed the Financial Strength Rating (FSR) of A (Excellent) and the Long-Term Issuer Credit Ratings (Long-Term ICRs) of "a+" (Excellent) of the core Blue Cross Blue Shield (BCBS)-branded ...

The failure of the dueling partisan plans all but guarantees the expiration of enhanced Affordable Care Act tax credits ...

Amy Schulman is the second veteran of the pharmaceutical industry that Elevance has added to its board this year.

The board of directors of Elevance Health (NYSE: ELV) today announced the appointment of Amy Schulman, a recognized healthcare executive, investor, and governance leader, as an independent director, ...